We’ve reached an exciting milestone at Newomics: we just commercially placed our 100th mass spec front-end system. We’re so proud that our customers now include 8 of the top 10 global biopharmaceutical companies and leading institutions in academia and biotech.

Our systems have contributed to successful customer applications in the development of biotherapeutics such as: Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.

In fact, system performance has been validated by 8 customers’ peer-reviewed papers, published in key industry journals like Analytical Chemistry and Journal of Chromatography A.